Esperion Therapeutics Stock (NASDAQ:ESPR)
Previous Close
$2.21
52W Range
$1.58 - $3.94
50D Avg
$2.45
200D Avg
$2.23
Market Cap
$445.30M
Avg Vol (3M)
$5.95M
Beta
0.95
Div Yield
-
ESPR Company Profile
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
ESPR Performance
Peer Comparison
| Ticker | Company |
|---|---|
| PBH | Prestige Consumer Healthcare Inc. |
| ALKS | Alkermes plc |
| ITCI | Intra-Cellular Therapies, Inc. |
| IRWD | Ironwood Pharmaceuticals, Inc. |
| LFCR | Lifecore Biomedical, Inc. |
| NBIX | Neurocrine Biosciences, Inc. |
| ANIP | ANI Pharmaceuticals, Inc. |
| RMTI | Rockwell Medical, Inc. |
| COLL | Collegium Pharmaceutical, Inc. |
| ELAN | Elanco Animal Health Incorporated |
| PAHC | Phibro Animal Health Corporation |
| SIGA | SIGA Technologies, Inc. |
| AVDL | Avadel Pharmaceuticals plc |
| KMDA | Kamada Ltd. |
| PCRX | Pacira BioSciences, Inc. |